• Available Formats
    • Availability
    • Priced From ( in USD )
    • Secure PDF 🔒
    • Immediate download
    • $150.00
    • Add to Cart

About This Item


Full Description

In 2022 ISPE worked with McKinsey and Company to provide technical and Chemistry, Manufacturing, and Controls (CMC) information on two workstreams to inform the newly, created European Commission Directorate-General, Health Emergency Preparedness and Response Authority (DG HERA). The workstreams were stockpiling antimicrobial resistance medical countermeasures, and flexible manufacturing and innovation countermeasures. This report summarizes the discussions and recommendations made by ISPE to the projects.

ISPE produced this report in response to a request from the US Department of Air Force Acquisition COVID-19 Task Force (DAF ACT) to advise regulatory, technical, and workforce elements favorable to creating a more robust and sustainable domestic pharmaceutical manufacturing base for Active Pharmaceutical Ingredients (APIs). The report lays out technical, regulatory and workforce changes that stakeholders in any country or region could consider to reduce the risks of API shortages to meet demands for essential medicines at any time, but particularly in pandemics and other emergencies.

ISPE has bundled these reports in keeping with its vision and mission and to provide solutions to complex pharmaceutical industry challenges and enhance efforts to develop, manufacture and reliably deliver quality medicines to patients. Together the reports reflect ISPE’s commitment to provide guidance on the supply of medicines to the people of every nation.